CHO-based Biosimilars Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global CHO-based Biosimilars Market Trends and Insights

Accelerating Loss of Exclusivity for High-Value Biologics

Blockbusters with annual sales of USD 200 billion to USD 400 billion will lose protection by 2030, with Keytruda, Stelara, and denosumab prominent among them ^{[1]Angus Liu, “The Great Patent Cliff Is Back, and This Time It Is Biological,” fiercepharma.com}. Many of these molecules carry complex glycosylation patterns that require high-fidelity CHO platforms, which discourage less-capitalized players but reward early movers who can quickly validate comparability. Premium pricing often holds during the first 18 months after launch, but late entrants face steep margin compression. The dynamic is splitting the CHO-based biosimilars market into a tier of scale-driven incumbents and a cluster of niche specialists. As a result, capacity reservation and early regulatory engagement are now more decisive than simply aligning with patent windows. Biosimilar uptake in immunology and insulin classes reached a modest penetration within 5 years of launch, compared with high adoption in oncology and ophthalmology, underscoring the persistence of formulary inertia in outpatient settings. This bifurcation suggests that regulatory interchangeability designations, while symbolically important, matter less than payer willingness to restructure formularies and absorb short-term disruption costs.

FDA ⁄ EMA Streamlining of Biosimilar Approval Pathways

By the end of 2025, the FDA had authorized 90 biosimilars across 20 reference molecules, achieving a 70% commercialization rate. Guidance released in September 2025 simplified glycosylation profiling using lectin microarrays, significantly reducing analytical risk ^{[2]U.S. FDA, “Glycosylation Profiling for Biosimilar Products,” fda.gov}. In Europe, the EMA’s interchangeability position statement spurred national substitution policies, accelerating adoption in France, Germany, and the Netherlands. Harmonized requirements have shortened clinical development timelines, which benefits resource-rich sponsors that can run concurrent global filings. Smaller firms are increasingly pairing with CDMOs to bridge knowledge gaps and amortize compliance costs across portfolios.

Payer Cost-Containment and Tendering Expand Access and Uptake

CVS’s Cordavis, Optum’s Nuvaila, and Cigna’s Quallent bypass traditional rebate schemes, pushing Humira biosimilar penetration surged significantly within one year of an April 2024 formulary shift. Europe’s smart tendering has delivered cumulative savings above EUR 10 billion since 2020. China’s volume-based procurement slashed prices by up to 80%, broadening access in tier-2 and tier-3 cities. Such cost-containment measures elevate the importance of flexible pricing, multi-SKU portfolios, and rapid supply ramp-up in the CHO-based biosimilars market.

EU Scientific Interchangeability and Adoption Mechanisms

The EMA affirmed scientific interchangeability in 2022, but roll-out across member states remains uneven. Automatic substitution for therapy-naïve patients is live in France, while Germany maintains physician discretion. Sandoz lifted biosimilar revenue 13% in 2025 by tailoring contracts country by country rather than adopting a single EU strategy. Regional tender quotas in Italy and hospital-level targets in Spain suggest gradual convergence, yet near-term market penetration gains will come mainly from early-adopter nations.

US PBM Rebate/Formulary Dynamics Delay Uptake in Pharmacy-Benefit Classes

Although payer consortia have accelerated adoption in oncology and ophthalmology, immunology, and insulin still see only 25% penetration five years post-launch due to entrenched rebate contracts that blunt net price advantages. Patient assistance programs further insulate originators, limiting near-term upside for CHO-based biosimilars in outpatient settings. Ongoing scrutiny by regulators and employers may pressure PBMs to adjust, but the timeline remains uncertain.

Biosimilar "Void" for Many Upcoming LoEs Due to Technical Complexity

Antibody-drug conjugates, bispecific antibodies, and Fc-engineered products approaching patent expiry lack active biosimilar pipelines because of conjugation, dual-target binding, and CQA hurdles. This gap preserves premium pricing for innovators and caps total savings achievable through substitution, tempering overall market acceleration.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Products & Services: Platform Partnerships Reshape Value Capture

Products contributed 60.35% of 2025 revenue. Monoclonal antibodies alone represented a significant share of global revenue in 2024, while Fc-fusion proteins and glycoprotein hormones trailed by wide margins ^{[3]BioProcess International, “Global Biosimilar Antibody Market,” bioprocessintl.com}. Continuous-processing facilities from Celltrion and Samsung Bioepis aim to keep per-gram COGS below USD 80, positioning integrated players to withstand price erosion. 

Services and platforms are expected to register a 12.65% CAGR through 2031, as emerging biotechs outsource to CDMOs. WuXi Biologics’ UITM platform achieved 18 g⁄L at 2,000 L GMP scale, illustrating how asset-light pathways help small sponsors sidestep heavy capital outlays. The arrangement also channels incremental volume into Asia-Pacific facilities, reinforcing the region’s role as a cost-optimized manufacturing hub in the CHO-based biosimilars market.

By Clinical Indication: Oncology Penetration Masks Immunology Inertia

Oncology held 55.67% of 2025 revenue. Trastuzumab, bevacizumab, and rituximab biosimilars have achieved significant market penetration in mature markets, underscoring the speed with which payers pivot once formulary barriers fall. 

Autoimmune and inflammatory uses are on track to expand at 11.26% annually through 2031. The surge follows private-label moves by CVS Cordavis, Optum Nuvaila, and Cigna Quallent, which lifted Humira biosimilar share significantly within a year of CVS’s April 2024 exclusion of the originator. Together, adalimumab, infliximab, and etanercept chase a USD 40 billion market, but they long sat below major share because rebates and patient-assistance programs hid net prices. With payer-driven swaps now proven, infliximab led 2022 revenue, and adalimumab is set for the fastest climb through 2030 as more formularies follow suit.

Geography Analysis

North America commanded a 42.15% share in 2025, supported by 90 FDA approvals and aggressive payer steering that drove significant Humira biosimilar uptake over 12 months. Growth is expected to plateau in saturated classes, yet upcoming LoEs for Keytruda and other oncology agents will spark new surges.

Europe combines lower absolute revenue with policy leadership; tendering delivered price drops in the United Kingdom, France, and Germany, saving health systems more than EUR 10 billion since 2020. Implementation of automatic substitution varies by country, compelling manufacturers to localize pricing and contracting strategies. 

Asia-Pacific is forecast to post a 12.34% CAGR to 2031, underpinned by China’s 87 cumulative approvals by year-end 2024 and Japan’s premium pricing for first-to-market products. India and South Korea extend regional production advantages, with Samsung Bioepis targeting 571,000 L capacity to anchor global supply. Markets in the Middle East, Africa, and South America remain nascent but show gradual progress through pilot tenders and local regulatory reforms, ultimately broadening the footprint of the CHO-based biosimilars market.